Genzyme Predicts $5 Bil. In Annual Revenues By 2010 From Current Portfolio
The firm is anticipating its forthcoming Pompe disease therapy Myozyme to contribute to growth starting in 2006.
The firm is anticipating its forthcoming Pompe disease therapy Myozyme to contribute to growth starting in 2006.